EISAI CO
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1941-12-06
- Employees
- 11K
- Market Cap
- $12B
- Website
- http://www.eisai.co.jp
Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom
Phase 4
Completed
- Conditions
- AsthmaChronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-10-29
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT01715493
A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation
Phase 3
Completed
- Conditions
- Hypervascular Tumor and Arteriovenous Malformation
- Interventions
- Device: E7040
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT01677624
Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT01645800
A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 940
- Registration Number
- NCT01618695
- Locations
- 🇹🇭
Facility #1, Tha Muang, Thailand
🇹🇭Facility #2, Tha Muang, Thailand
🇹🇭Facility #3, Tha Muang, Thailand
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 351
- Registration Number
- NCT01539031
A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2012-06-27
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT01506752
A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult Males
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2012-01-10
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT01506739
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
- First Posted Date
- 2011-11-02
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 963
- Registration Number
- NCT01463891
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT01458249
E2022 Patch Formulation Multiple Dose Study
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT01450839